newsfilter
← Latest News
PR Newswire·

FDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat...